Advertisement

Novo Nordisk's once-weekly basal insulin icodec recommended for marketing approval in Europe

Novo Nordisk hopes to launch experimental obesity drug this decade

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk on Thursday said its once-weekly basal insulin icodec for treatment of diabetes in adults had received a recommendation for marketing authorisation from the European Medicines Agency's human medicines committee.

(Reporting by Stine Jacobsen, eiditn by Anna Ringstrom)